MicroPort MedBot develops and sells medical robotic systems, including robotic platforms for laparoscopic, orthopedic and vascular surgical procedures.
MicroPort MedBot is a Chinese surgical-robot maker (HKEX:2252) whose Toumai laparoscopic robot has 300+ commercial orders across 60 markets, with its most recent 100 orders taking 120 days versus about 1,000 days for the first 100. 2025 revenue was RMB 551M (~$76M, doubled YoY, 73% exports), and an H1-26 profit alert (July 2026) signals its first profit (RMB 28-40M), reversing a prior loss at a ~62% gross margin. The annual-report cross-check, procedure volumes, and the US regulatory path are open.
1 facts on file. Members see all of them with the source link.
Traction: deployment, production, commercials, progress. Capability: technology, positioning, firepower, leverage.
MicroPort MedBot develops and sells medical robotic systems, including robotic platforms for laparoscopic, orthopedic and vascular surgical procedures. MicroPort MedBot is a Chinese surgical-robot maker (HKEX:2252) whose Toumai laparoscopic robot has 300+ commercial orders across 60 markets, with its most recent 100 orders taking 120 days versus about 1,000 days for the first 100. 2025 revenue was RMB 551M (~$76M, doubled YoY, 73% exports), and an H1-26 profit alert (July 2026) signals its first profit (RMB 28-40M), reversing a prior loss at a ~6
MicroPort MedBot is on the Robotics watchlist list of Frontier Tech Intelligence with a score of 74 out of 100, below the Top 100.
MicroPort MedBot is based in Shanghai, Shanghai, China. Stage: Public.
Subscribers see the full file, every signal, the live ranking and the questions the signals answer: where money moved, who controls the layer, where supply is constrained. $99 a month, 7-day trial. What Frontier Tech Intelligence is →